Nanoformulations of doxorubicin: How far have we come and where do we go from here?
Само за регистроване кориснике
Mrđanović, Jasminka Ž.
Jović, Danica S.
Srđenović, Branislava U.
Đorđević, Aleksandar N.
Чланак у часопису (Објављена верзија)
© 2018 IOP Publishing Ltd
МетаподациПриказ свих података о документу
Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present ...an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior.
Кључне речи:anticancer activity / doxorubicin / nanocarrier / nanodrug delivery / nanoformulation / nanopharmaceuticals
Извор:Nanotechnology, 2018, 29, 33, 332002-
ISSN: 0957-4484 (print); 1361-6528 (electronic)